Navigation Links
Delcath to Present at the Lazard Healthcare Conference on November 15
Date:11/11/2011

esults to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
2. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
3. FDA Schedules Delcath Pre-New Drug Application Meeting Date
4. Delcath Announces Completion of Regulatory Notification Process in New Zealand
5. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
6. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
7. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
8. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
9. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
10. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
11. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
...  BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... license and development agreement with Endo Pharmaceuticals (Nasdaq: ... to develop and commercialize BEMA Buprenorphine for the ... patented and proven BioErodible MucoAdhesive (BEMA) technology to ...
... conjunction with its fourth quarter 2011 earnings release (expected to ... Inc. (NYSE: CVD ) is pleased to invite ... will be broadcast live over the Internet on Thursday, January ... , What:       , , , Covance Fourth Quarter 2011 Earnings ...
Cached Medicine Technology:BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 2BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 3BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 4BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 5
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... pain today are much less likely to die, or to experience ... according to a new international study. ,It's the first ... rate of heart failure and death over such a short time ... change occurred at the same time that hospitals increased their use ...
... failed to improve symptoms of moderate to severe chronic ... multi-center trial. ,The results of the ... the first issue of the May American Journal of ... Thoracic Society. ,According to an editorial commenting ...
... Junior doctors who do not get training posts through ... further misery because the government is stalling on ... warns. ,Latest figures show that 34,250 doctors ... The government has so far given no commitment that ...
... cream for enhancing sexual desire in female cancer survivors did ... Mayo clinic has shown. ,A low sex ... to a previous study which pointed a link between androgen ... levels, this new study was conducted on 150 post menopausal ...
... is now infusing roasted sunflower seeds with caffeine ... provide players and other people the extra energy needed to ... been under development since an year, are grown in North ... Products) plant at Willow Lake where caffeine, taurine, lysine and ...
... there is no hard and fast rule as to how a ... more than glad to endorse that view as standard positions ... motherly feelings to override. , Take the case of ... when her daughter Deborah was born. ,As manager of ...
Cached Medicine News:Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3
... solid made, manual plate washer for ... dispense and aspirate function ensure proper ... a stand and all necessary tubings. ... as well as any bottles for ...
... MP-1200 is a compact and simple ... internal micropumps enable the system both ... all types of microtiter well. MW-1200 ... in rows of 8 wells or ...
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
Medicine Products: